Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Rayner

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Hybridoma (2005)|August 19, 2008
A novel approach to development of monoclonal antibodies using native antigen for immunization and recombinant antigen for screeningWei-Gang Hu, Junfei Yin, Scott Jager, et al.
Cornea|August 2, 2007
Autosomal recessive CHED associated with novel compound heterozygous mutations in SLC4A11Anthony J Aldave, Vivek S Yellore, Nirit Bourla, et al.
Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Surgical Oncology|August 1, 1984
The effect of 1,2-dimethylhydrazine (DMH) carcinogenesis on peripheral T cell subsets in the Wistar Furth ratD S Ross, G Steele, M L Rodrick, et al.
Hepatology (Baltimore, Md.)|December 1, 1996
Prevalence of herpesviridae and hepatitis B virus DNA in the liver of patients with non-A, non-B fulminant hepatic failureA Mason, R Sallie, R Perrillo, et al.
Investigative Ophthalmology & Visual Science|June 27, 2006
No VSX1 gene mutations associated with keratoconusAnthony J Aldave, Vivek S Yellore, Andrew K Salem, et al.
American Journal of Ophthalmology|October 19, 2004
Corneal pharmacokinetics of topically applied azithromycin and clarithromycinJonas J Kuehne, Anna Lisa T Yu, Gary N Holland, et al.
The Journal of Infectious Diseases|April 1, 1990
An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cellsI B Weisfuse, D J Graham, M Will, et al.
Cell Death & Disease|March 24, 2017
Kaiso depletion attenuates the growth and survival of triple negative breast cancer cellsBlessing I Bassey-Archibong, Lyndsay G A Rayner, Shawn M Hercules, et al.
Cancer Research|August 1, 1988
Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humansD H Boldt, B J Mills, B T Gemlo, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Hybridoma (2005)|August 19, 2008
A novel approach to development of monoclonal antibodies using native antigen for immunization and recombinant antigen for screeningWei-Gang Hu, Junfei Yin, Scott Jager, et al.
Cornea|August 2, 2007
Autosomal recessive CHED associated with novel compound heterozygous mutations in SLC4A11Anthony J Aldave, Vivek S Yellore, Nirit Bourla, et al.
Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Surgical Oncology|August 1, 1984
The effect of 1,2-dimethylhydrazine (DMH) carcinogenesis on peripheral T cell subsets in the Wistar Furth ratD S Ross, G Steele, M L Rodrick, et al.
Hepatology (Baltimore, Md.)|December 1, 1996
Prevalence of herpesviridae and hepatitis B virus DNA in the liver of patients with non-A, non-B fulminant hepatic failureA Mason, R Sallie, R Perrillo, et al.
Investigative Ophthalmology & Visual Science|June 27, 2006
No VSX1 gene mutations associated with keratoconusAnthony J Aldave, Vivek S Yellore, Andrew K Salem, et al.
American Journal of Ophthalmology|October 19, 2004
Corneal pharmacokinetics of topically applied azithromycin and clarithromycinJonas J Kuehne, Anna Lisa T Yu, Gary N Holland, et al.
The Journal of Infectious Diseases|April 1, 1990
An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cellsI B Weisfuse, D J Graham, M Will, et al.
Cell Death & Disease|March 24, 2017
Kaiso depletion attenuates the growth and survival of triple negative breast cancer cellsBlessing I Bassey-Archibong, Lyndsay G A Rayner, Shawn M Hercules, et al.
Cancer Research|August 1, 1988
Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humansD H Boldt, B J Mills, B T Gemlo, et al.
Pageof 16